10-Q: Regen BioPharma Reports Q1 2024 Results, Cites Ongoing Need for Financing

Regen BioPharma's Q1 2024 report shows a net loss of $349,760 and highlights the company's ongoing need for additional financing.

Summary

• Regen BioPharma reported a net loss of $349,760 for the quarter ended December 31, 2023, compared to a net income of $1,635,730 for the same period in 2022.
• The company's operating loss was $122,782 for the quarter, a significant improvement from the $463,867 loss in the prior year's quarter.
• Total revenue remained consistent at $59,065 for both the current and prior year's quarter.
• The company's cash balance was $124,497 as of December 31, 2023, with total liabilities of $5,400,991.
• Regen Biopharma has a significant accumulated deficit of $20,098,623 as of December 31, 2023.
• The company is actively seeking additional financing to meet its cash requirements over the next twelve months.
• The company entered into an equity line agreement with Coventry Enterprises LLC for up to $10,000,000 in financing over 36 months.
• During the quarter, Regen Biopharma issued 244,199 common shares for $212,297 under the equity line agreement.

Sentiment

Score: 3

Explanation: The document indicates a weak financial position with a net loss, low cash reserves, and a significant accumulated deficit. While there are some positive aspects, such as the improved operating loss and the equity line agreement, the overall sentiment is negative due to the company's financial instability and reliance on further financing.

Positives

• The operating loss improved significantly from $463,867 in Q1 2023 to $122,782 in Q1 2024.
• The company secured an equity line agreement with Coventry Enterprises LLC, providing access to up to $10,000,000 in financing.
• The company successfully raised $212,297 through the sale of common shares under the equity line agreement during the quarter.
• The company reduced its current notes payable by approximately 48.6% due to repayments.

Negatives

• The company reported a net loss of $349,760 for the quarter ended December 31, 2023.
• The company has a significant accumulated deficit of $20,098,623.
• The company's cash balance is low at $124,497, with total liabilities of $5,400,991.
• The company's investment securities related to Zander Therapeutics were revalued, resulting in a significant decrease in fair value.
• The company states it will not be able to satisfy its cash requirements over the next twelve months without additional financing.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing and achieving profitability.
• The company has a significant accumulated deficit and low cash reserves.
• The company's reliance on the equity line agreement with Coventry Enterprises LLC for financing exposes it to risks associated with the terms and conditions of the agreement.
• The company's investment in Zander Therapeutics is subject to valuation fluctuations and may not provide the expected returns.
• The company's dependence on related party transactions could pose a risk to its financial stability.

Future Outlook

The company states it will not be able to satisfy its cash requirements over the next twelve months and shall be required to seek additional financing.

Management Comments

• The company's Principal Executive Officer and Principal Financial Officer have concluded that the company's disclosure controls and procedures are effective at a reasonable assurance level.
• The company's management believes that it will not be able to satisfy its cash requirements over the next twelve months and will need to seek additional financing.

Industry Context

Regen Biopharma is a small biotechnology company focused on developing regenerative medical applications. The company's financial results reflect the challenges faced by early-stage biotech companies, including high research and development costs and the need for significant capital investment. The company's focus on licensing its technology after Phase I or II clinical trials is a common strategy in the biotech industry to mitigate risk and generate revenue.

Comparison to Industry Standards

• Regen Biopharma's financial situation is not uncommon for early-stage biotech companies, many of which operate at a loss while developing their technologies.
• Compared to companies like Celldex Therapeutics (CLDX) or Agenus (AGEN), which are also in the clinical-stage biotech space, Regen's revenue is significantly lower, reflecting its early stage of development.
• Companies like these often rely on equity financing and strategic partnerships to fund their operations, similar to Regen's approach with the equity line agreement.
• The revaluation of investment securities in Zander Therapeutics highlights the risk associated with investments in private companies, a common challenge for smaller biotech firms.
• The company's reliance on convertible notes and related party transactions is also a common practice for early-stage companies, but it can also introduce additional risks.

Related Party Transactions

• The company has significant related party transactions, including licensing agreements and convertible notes with Zander Therapeutics, Inc., which is under common control.
• The company is indebted to David R. Koos, the company's sole officer and director, in the amount of $710.
• The company subleases office space from BST Partners, which is controlled by David Koos.

Stakeholder Impact

• Shareholders face the risk of further dilution due to the company's need for additional financing.
• Employees may be concerned about the company's financial stability and its ability to continue operations.
• Customers and suppliers may be hesitant to engage with the company due to its financial challenges.
• Creditors face the risk of non-payment due to the company's low cash reserves and high liabilities.

Next Steps

• The company will continue to seek additional financing to meet its cash requirements.
• The company will continue to develop its regenerative medical applications.
• The company will continue to monitor the performance of its investment in Zander Therapeutics.

Key Dates

Keywords

Regen BioPharma, Biotechnology, Financial Results, Equity Financing, NR2F6, Preferred Stock, Convertible Notes, Zander Therapeutics, Coventry Enterprises, Operating Loss, Net Loss, Going Concern